Because all the FDA has said is that they can refile the application.
They have done this twice in the past. It sounds like the FDA may now be ok with the potency, but have they changed their minds on needing further evidence?
More specifics would be nice.
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-26
-
- There are more pages in this discussion • 1,071 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |